Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome

British Journal of Dermatology

Volumn 142, Issue 3, 2000, Pages 461-467

  Dunphy, J ^a   Oliver, M ^a   Rands, A L ^b   Lovell, C R ^c   McHugh, N J ^a,b  

^a ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

Antineutrophil cytoplasmic antibodies; HLA class II; Lupus erythematosus; Minocycline

Indexed keywords

HLA ANTIGEN CLASS 2; MINOCYCLINE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ACNE; ADOLESCENT; ADULT; ALLELE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE MARKER; DISEASE PREDISPOSITION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; SKIN LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MINOCYCLINE;

EID: 0034102550     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03357.x     Document Type: Article

References (32)

1. 1 Byrne PAC, Williams BD, Pritchard MH. Minocyclin-related lupus. Br J Rheumatol 1994; 33: 674-6.
2. 2 Bulgen DY. Minocycline-related lupus. (Letter.) Br J Rheumatol 1995; 34: 398.
3. 3 Gough A, Chapman S, Wagstaff K et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J 1996; 312: 169-72.
4. 4 Knowles SR, Shapiro L, Shear NH. Serious adverse reaction induced by minocycline. Arch Dermatol 1996; 132: 934-9.
5. 5 Masson C, Chevailler A, Pascaretti C et al. Minocycline related lupus. J Rheumatol 1996; 23: 2160-1.
6. 6 Malcolm A, Heap TR, Eckstein RP, Lunzer MR. Minocycline-induced liver injury. Am J Gastroenterol 1996; 91: 1641-3.
7. 7 Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis 1996; 55: 769-71.
8. 8 Golstein PE, Deviere J, Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997; 92: 143-6.
9. 9 Knights SE, Leandro MJ, Khamashta M, Hughes GRV. Minocycline-induced arthritis. Clin Exp Rheumatol 1998; 16: 587-90.
10. 10 Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996; 134: 693-5.
11. 11 Sturkenboom MCJ, Meier CR, Jick H, Stricker BHC. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999; 159: 493-7.
12. 12 D'Cruz D, Chesser AMS, Lightowler C et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol 1995; 34: 1090-1.
13. 13 Nassberger L, Sjoholm AG, Jonsson H. Autoantibodies against neutrophil cytoplasmic components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 1990; 81: 380-3.
14. 14 Cambridge G, Wallace H, Bernstein RM, Leaker B. Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythemalosus and vasculitis. Br J Rheumatol 1994; 33: 109-14.
15. 15 Elkayam O, Levartovsky D, Brautbar C et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105: 484-7.
16. 16 Rubin RL, Nusinow SR, Johnson AD. Serologic changes during induction of lupus-like disease by procainamide. Am J Med 1986; 80: 999-1002.
17. 17 Reidenberg MM. Aromatic amines and the pathogenesis of lupus erythematosus. Am J Med 1983; 75: 1037-42.
18. 18 Batchelor JR, Welsh KI, Tinoco RM. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980; i: 1107-9.
19. 19 Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-35.
20. 20 Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993; 41: 119-34.
21. 21 Kaneoka H, Hsu K-C, Takeda Y et al. Molecular genetic analysis of HLA-DR and HLA-DQ genes among anti-U1 - 70-kd autoantibody positive connective tissue disease patients. Arthritis Rheum 1992; 35: 83-94.
22. 22 Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988; 27: 272-5.
23. 23 Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing glomerulonephritis. N Engl J Med 1988; 318: 1651-7.
24. 24 Short AK, Lockwood CM. Antigen-specificity in hydralazine associated ANCA positive systemic vasculitis. QJ Med 1995; 88: 775-83.
25. 25 Pauzner R, Urowitz M, Gladman D, Gough J. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. J Rheumatol 1994; 21: 1670-3.
26. 26 Morcos M, Zimmerman F, Radsak M et al. Autoantibodies to polymorphonuclear elastase do not inhibit but enhance elastase activity. Am J Kidney Dis 1998; 31: 978-85.
27. 27 Pollard KM, Lee DK, Casiano CA et al. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J Immunol 1997; 158: 3521-8.
28. 28 Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994; 266: 810-13.
29. 29 Taurog A, Dorris ML, Doerge DR. Minocycline and the thyroid. Antithyroid effects of the drug, and the role of thyroid peroxidase in minocycline-induced black pigmentation of the gland. Thyroid 1996; 6: 211-19.
30. 30 Nilges MJ, Enochs WS, Swartz HM. Identification and characterization of a tetracycline semiquinone formed during the oxidation of minocycline. J Org Chem 1991; 56: 5623-30.
31. 31 Reveille JD, Durban E, MacLeod-St Clair MJ et al. Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase 1 autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992; 90: 973-80.
32. 32 Whyte J, Artlett C, Harvey G et al. HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives. J Autoimmun 1994; 7: 509-20.